ARQT Share Price Performance
US$25.38
8.00 (46.07%)
31.2% undervalued intrinsic discount
US$36.88
Fair Value
Price US$25.38
AnalystConsensusTarget US$36.88
Coward_Nutlick US$39.99
Fair ValueUS$36.88
Share Pricen/a
Arcutis Biotherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 65 Fair Values set on narratives written by author
ARQT Community Narratives
AN
Fair Value
·Fair Value US$36.88 31.2% undervalued intrinsic discount
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
0users have liked this narrative
0users have commented on this narrative
35users have followed this narrative
CO
Fair Value
·Fair Value US$39.99 36.5% undervalued intrinsic discount
Very Bullish
5users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Arcutis Biotherapeutics
36.5% undervalued intrinsic discount
Very Bullish
View narrativeCO
Updated 18 Jan
Arcutis Biotherapeutics
31.2% undervalued intrinsic discount
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
View narrativeAN
Updated 8 Aug
Trending Discussion
No trending discussion available.
Recently Updated Narratives
CO
Very Bullish
Fair Value: US$39.99 36.5% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
AN
ARQT: Expanded Pediatric Dermatology Indications Will Drive Future Upside Potential
Fair Value: US$36.88 31.2% undervalued intrinsic discount
35 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arcutis Biotherapeutics, Inc. Key Details
About ARQT
- Founded
- 2016
- Employees
- 354
- CEO
- WebsiteView website
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
